Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Saccharomyces boulardii (Alde Medi Impex, 3c2c97)
- Development stage
- Unknown
- Lead developer
- Alde Medi Impex
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Florill Capsules is a probiotic supplement containing the beneficial yeast *Saccharomyces boulardii*. Developed and marketed by Alde Medi Impex, it is used to restore and maintain the natural balance of intestinal microflora. It is primarily indicated for the prevention and management of acute infectious diarrhea, antibiotic-associated diarrhea, and symptoms associated with irritable bowel syndrome (IBS). *Saccharomyces boulardii* works by competitively inhibiting the adhesion and colonization of pathogenic microorganisms in the gastrointestinal tract, neutralizing bacterial toxins, and modulating local immune responses to support gut health.
- Brand names
- Florill Capsules
- Other names
- Saccharomyces boulardiiSaccharomyces cerevisiae var. boulardii
02
Targets
PA (Influenza polymerase acidic protein)αMβ2 (Integrin αMβ2)CLEC7A (Dectin-1)LTA (Lymphotoxin-alpha)TLR (Toll-like receptors)ITGA2/ITGB1 (Integrin alpha-2/beta-1 receptor)
Beyond the preview
Go deeper on Saccharomyces boulardii (Alde Medi Impex, 3c2c97).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Saccharomyces boulardii (Alde Medi Impex, 3c2c97).